NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday recommended approval of alpelisib (Novartis' Piqray) in combination with fulvestrant for PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer that has progressed on endocrine therapy. The drug is recommended for women who are postmenopausal and men with breast cancer.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.